Swipe om te navigeren naar een ander artikel
Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands
Department of Cardiology, University Medical Center Utrecht, Room E.01.207, PO Box 85500,3508 GA Utrecht, the Netherlands
Objectives. To evaluate clinical events in a specifically selected cohort of patients with obstructive coronary artery disease (CAD), using a new generation thin-strut bare cobalt-chromium coronary stent.
Methods. Patients with single- or multi-vessel, stable or unstable CAD eligible for percutaneous implantation of at least one bare cobalt-chromium stent were evaluated in a single-centre registry. Prospective pre-specified criteria for bare cobalt-chromium stent implantation in our centre were: any acute ST-elevation myocardial infarction (MI), otherwise 1) de novo coronary lesion, and 2) lesion length <20 mm, and 3) reference vessel diameter >2.6 mm, and 4) no diabetes, unless reference vessel diameter >3.5 mm. Endpoints, retrospectively collected, were death, MI and clinically driven target-lesion revascularisation (TLR) and target-vessel revascularisation (TVR) after 12 months.
Results. Between September 2005 and June 2007, 712 patients (48.7% one-vessel, 29.9% two-vessel, 20% three-vessel and 1.4% left main disease; 7.9% diabetics) were treated with 800 bare cobalt-chromium stents, for stable angina (40.9%), unstable angina (20.9%) or acute ST-elevation MI (38.2%). The procedural success rate was 99.3%. Peri-procedural MI rate was 2.2% in the semi-elective group. At 12 months there were 17 deaths (2.4%), of which nine non-cardiac, 20 (2.8%) MI, 19 (2.7%) TLR and 29 (4.1%) TVR. Early and late definite stent thrombosis occurred in four (0.6%) and three (0.4%) patients, respectively.
Conclusion. A strategy aimed at minimising drug-eluting stent use and combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent is safe and effective at one-year clinical follow-up. (Neth Heart J 2010;18:486-92.)
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361: 13-20.
Schomig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A. A meta-analysis of 17 randomized trials of percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol. 2008; 52: 894-904.
Biondi-Zoccai G, Abbate A, Agostoni P, Testa L, Burzotta F, Lotrionte et al. Long-term benefits of an early invasive management in acute coronary syndromes depend on intra-coronary stenting and aggressive anti-platelet treatment: a meta-regression. Am Heart J. 2005; 149: 504-11.
Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: a hierarchical ayesian meta-analysis. Ann Intern Med. 2003; 138: 777-86.
Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation. 2008; 118: 1146-54.
Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare metal stents: a collaborative network meta-analysis. Lancet. 2007; 370: 937-48.
Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006; 119: 1056-61.
Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48: 193-202.
Filion KB, Roy AM, Baboushkin T, Rinfret S, Eisenberg MJ. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis. Am J Cardiol. 2009; 103: 345-9.
Sangiorgi G, Melzi G, Agostoni P, Cola C, Clementi F, Romitelli P, et al. Engineering aspects of stents design and their translation into clinical practice. Ann Ist Super Sanita. 2007; 43: 89-100.
Hoffmann R, Mintz GS, Haager PK, Bozoglu T, Grube E, Gross M, et al. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. Am J Cardiol. 2002; 89: 1360-4.
Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schühlen H, Pache J, et al. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv. 2000; 50: 290-7.
Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol. 2002; 40: 403-9.
Kastrati A, Mehilli J, .Dirschinger J, Dotzer F, Schunhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR STEREO) trial. Circulation. 2001; 103: 2816-21.
Pache J, Kastrati A, Mehilli J, Schunhlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003; 41: 1283-8.
Rittersma SZ, de Winter RJ, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol. 2004; 93: 477-80.
Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, et al; Guidant Multi-Link Vision Stent Registry Investigators. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol. 2003; 92: 463-6.
de Man FH, Stella PR, Nathoe H, Kirkels H, Hamer B, Meijburg HW, et al. Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. Neth Heart J. 2007; 15: 382-6.
Product specifications Skylor stent system. Available at www.invatec.com/tool/home.php?s=0,1,55,56,98. Access: 5 February 2009.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Es GA, et al, on behalf of the Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007; 115: 2344-51.
Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001; 103: 192-5.
Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004; 100: 2361-7.
Diner AC, Bogousslavsky J, Brass LM. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364: 331-7.
Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-30.
Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113: 1108-13.
Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78.
Quizhpe AR, Feres F, de Ribamar Costa J Jr, Abizaid A, Maldonado G, Costa R, Abizaid A, Cano M, Moreira AC, Staico R, Mattos LA, Tanajura LF, Chaves A, Centemero M, Sousa AM, Sousa JE. Drug-eluting stents vs. bare metal stents for the treatment of large coronary vessels. Am Heart J 2007;154:373-378.
Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, Hunziker P, Mueller C, Nietlispach F, et al; BASKET. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J. 2009; 30: 16-24.
Pache J, Dibra A, Mehilli J, Dirschinger J, Schömig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J. 2005; 26: 1262-8.
Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, et al. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv. 2007; 69: 790-8.
Daemen J, Tanimoto S, García-García HM, Kukreja N, van de Sande M, Sianos G, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol. 2007; 99:1027-32.
Steg PG, Fox KA, Eagle KA, Furman M, Van de Werf F, Montalescot G, et al.; Global Registry of Acute Coronary Events (GRACE) Investigators. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J. 2009; 30: 321-9.
Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart. J 2007; 28: 2706-13.
Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, et al.; DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261-7.
Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ; Driver investigators. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol. 2005;95:8-12.
Legrand V, Kelbaek H, Hauptmann KE, Glogar D, Rutsch W, Grollier G, et al.; CLASS Investigators. Clinical and angiographic analysis with a cobalt alloy coronary stent (driver) in stable and unstable angina pectoris. Am J Cardiol. 2006;97:349-52.
Strehblow C, Gyöngyösi M, Zenker G, Wallner H, Heigert M, Siostrzonek P, et al.. Small vessel stenting with cobalt-chromium stents (Arthos Pico) in a real world setting. Coron Artery Dis. 2007;18:305-11.
Burzotta F, Trani C, Todaro D, Mazzari MA, Porto I, De Vita MR, et al. Outcome of patients treated by a novel thin-strut cobalt-chromium stent in the drug-eluting stent era: Results of the SKICE (Skylor in real world practICE) registry. Cathet Cardiovasc Interv. 2009; 73: 457-65.
Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, et al.; BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. Am Heart J. 2008; 155: 609-14.
Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol. 2005; 45: 1206-12.
- One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent
P. R. Stella
H. M. Nathoe
S. Hoseyni Guyomi
B. J. Hamer
T. X. Wildbergh
P. A. Doevendans
E. Van Belle
- Bohn Stafleu van Loghum